医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

Gynesonics Completes $46 Million Equity Financing

2015年11月17日 PM11:00
このエントリーをはてなブックマークに追加


 

REDWOOD CITY, Calif.

Gynesonics, a women’s healthcare company focused on the development of minimally invasive solutions for symptomatic uterine fibroids, today announced $2.9 million of additional equity financing, increasing the aggregate amount raised to $46 million, completing this round of financing.

Rockville, MD-based Novit Ventures LP, the investment arm of USP Group, one of the most successful privately-held healthcare companies active in both the European Union and North America, was the primary investor in this new addition to the equity financing. Other investors previously announced include lead investors, Endeavour Vision and Abingworth, as well as, HealthCrest, InterWest Partners, Advanced Technology Ventures (ATV), HBM Partners, Correlation Ventures and Hercules Technology Growth Capital.

The proceeds from the equity financing will continue to fund Gynesonics’ strategic initiatives and clinical plan in the U.S and globally, including the FDA pivotal trial of the latest generation of the Company’s Sonata™ System, an innovative, uterus-preserving, incision-free approach to the treatment of a wide range of symptomatic uterine fibroid types.

“Our financial partners have great confidence in the potential of the Sonata Technology platform to make a significant improvement in the lives of millions of women around the world who suffer from symptomatic uterine fibroids,” said Christopher M. Owens, President and CEO of Gynesonics. “This total financing significantly increases the depth of our financial backing, enabling us to move forward aggressively in executing our clinical research initiatives, R&D priorities and initial European targeted commercialization.”

According to medical literature, about 70-80 percent of women in the U.S. will develop uterine fibroids by age 50 with a significant proportion of the fibroids causing symptoms. In addition, according to the New England Journal of Medicine, approximately 200,000 hysterectomies are performed in the United States each year because of symptomatic fibroids.

About Sonata System

The Sonata™ System, the next generation of Gynesonics’ technology platform (the previous generation referred to as VizAblate), uses radiofrequency energy to ablate fibroids under intrauterine sonography guidance. The Sonata™ System, including the SMART Targeting Guide, enables the operator to target fibroids and optimize ablations within them. Sonata™ System’s design provides a straightforward, transcervical access for a uterus preserving, incision-free fibroid treatment. This intrauterine approach is designed to avoid the peritoneal cavity. In October 2014, Gynesonics announced FDA approval of the SONATA IDE pivotal trial for their latest generation Sonata™ System.

About Gynesonics

Gynesonics is a women’s healthcare company focused on minimally invasive solutions for symptomatic uterine fibroids. Gynesonics has developed the Sonata™ System for the transcervical treatment of symptomatic uterine fibroids under intrauterine sonography guidance. The Sonata™ System is CE Marked and approved for sale in the European Union. Sonata™ System is not available for sale in the United States. Gynesonics is a privately held company with headquarters in Redwood City, CA.

View source version on businesswire.com: http://www.businesswire.com/news/home/20151117006072/en/

CONTACT

Gynesonics
Chris Owens, +1.650.216.3860
President and CEO
www.gynesonics.com

Related Posts Plugin for WordPress, Blogger...
 

同じカテゴリーの記事 

  • Hallstar的新款光稳定剂AvoBrite®在交付卓越防晒产品的同时解决客户面临的监管挑战
  • ホールスターの新しい光安定剤AvoBrite®が、規制に関する課題を解決しつつ、卓越した光防御機能を提供
  • Clinigen Acquires Japan’s Largest Supplier of Unlicensed Medicines
  • Konica Minolta and Innovation Network Corporation of Japan Close Acquisition of Ambry Genetics
  • Median Technologies Appoints Vivian Wang as General Manager, China and Takashi Hayashi as Managing Director, Japan